OBJECTIVE: This study investigated the effects of hyperbaric oxygen (HBO) therapy on the cardiovascular alteration (e.g. mean arterial pressure, vascular reactivity of thoracic aorta rings changes) caused by zymosan in rats. DESIGN: Rats. SETTING: University research laboratory. INTERVENTION AND MEASUREMENTS: We investigated the effects of HBO therapy (2 ATA at the fourth and eleventh hours after study onset) on the cardiovascular alteration caused by zymosan (500 mg/kg, administered i.p. as a suspension in saline) in rats. Cardiovascular alterations were assessed 18 h after administration of zymosan and/or HBO therapy. RESULTS: Treatment of rats with HBO therapy attenuated the vasoplegic response to zymosan. In fact, the analysis of arterial pressure curves revealed no signs of vasoplegic shock. The aorta rings of animals treated with zymosan and HBO had a significantly increased contraction to norepinephrine (NE) and endothelin-1 (ET-1) and dilation to acetylcholine (ACh) compared with the zymosan group. The HBO therapy also attenuated the increase of malondialdehyde (MDA) levels caused by zymosan in the aorta. Immunohistochemical analysis for nitrotyrosine and for iNOS revealed positive staining in the aorta from zymosan-treated rats. The degree of staining for nitrotyrosine and iNOS was markedly reduced in tissue sections obtained from zymosan-rats treated with HBO therapy. CONCLUSION: This study provides the first evidence that HBO therapy attenuates the degree of zymosan-induced cardiovascular derangement in the rat.
OBJECTIVE: This study investigated the effects of hyperbaric oxygen (HBO) therapy on the cardiovascular alteration (e.g. mean arterial pressure, vascular reactivity of thoracic aorta rings changes) caused by zymosan in rats. DESIGN:Rats. SETTING: University research laboratory. INTERVENTION AND MEASUREMENTS: We investigated the effects of HBO therapy (2 ATA at the fourth and eleventh hours after study onset) on the cardiovascular alteration caused by zymosan (500 mg/kg, administered i.p. as a suspension in saline) in rats. Cardiovascular alterations were assessed 18 h after administration of zymosan and/or HBO therapy. RESULTS: Treatment of rats with HBO therapy attenuated the vasoplegic response to zymosan. In fact, the analysis of arterial pressure curves revealed no signs of vasoplegic shock. The aorta rings of animals treated with zymosan and HBO had a significantly increased contraction to norepinephrine (NE) and endothelin-1 (ET-1) and dilation to acetylcholine (ACh) compared with the zymosan group. The HBO therapy also attenuated the increase of malondialdehyde (MDA) levels caused by zymosan in the aorta. Immunohistochemical analysis for nitrotyrosine and for iNOS revealed positive staining in the aorta from zymosan-treated rats. The degree of staining for nitrotyrosine and iNOS was markedly reduced in tissue sections obtained from zymosan-rats treated with HBO therapy. CONCLUSION: This study provides the first evidence that HBO therapy attenuates the degree of zymosan-induced cardiovascular derangement in the rat.
Authors: S Cuzzocrea; B Zingarelli; L Sautebin; A Rizzo; C Crisafulli; G M Campo; G Costantino; G Calapai; F Nava; M Di Rosa; A P Caputi Journal: Shock Date: 1997-10 Impact factor: 3.454
Authors: C Luongo; F Imperatore; M G Matera; G Mangoni; M Marmo; A Baroni; P Catalanotti; F Rossi; A Filippelli Journal: Undersea Hyperb Med Date: 1999 Impact factor: 0.698
Authors: S Cuzzocrea; F Imperatore; G Costantino; C Luongo; E Mazzon; M A Scafuro; G Mangoni; A P Caputi; F Rossi; A Filippelli Journal: Shock Date: 2000-03 Impact factor: 3.454
Authors: Francesco Imperatore; Salvatore Cuzzocrea; Domenico De Lucia; Marcella Sessa; Barbara Rinaldi; Annalisa Capuano; Giovanni Liguori; Amelia Filippelli; Francesco Rossi Journal: Intensive Care Med Date: 2006-09-15 Impact factor: 17.440
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker; Benoit Vallet Journal: Intensive Care Med Date: 2005-02-18 Impact factor: 17.440
Authors: Jae-Min Yuk; Dong-Min Shin; Hye-Mi Lee; Jwa-Jin Kim; Sun-Woong Kim; Hyo Sun Jin; Chul-Su Yang; Kyeong Ah Park; Dipanjan Chanda; Don-Kyu Kim; Song Mei Huang; Sang Ki Lee; Chul-Ho Lee; Jin-Man Kim; Chang-Hwa Song; Soo Young Lee; Gang Min Hur; David D Moore; Hueng-Sik Choi; Eun-Kyeong Jo Journal: Nat Immunol Date: 2011-07-03 Impact factor: 25.606
Authors: Barbara Rinaldi; Salvatore Cuzzocrea; Maria Donniacuo; Annalisa Capuano; Donatella Di Palma; Francesco Imperatore; Emanuela Mazzon; Rosanna Di Paola; Loredana Sodano; Francesco Rossi Journal: Intensive Care Med Date: 2011-05-13 Impact factor: 17.440